

Allan D Struthers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3796854/publications.pdf>

Version: 2024-02-01

282
papers

14,934
citations

15504

65
h-index

22166

113
g-index

285
all docs

285
docs citations

285
times ranked

14525
citing authors

#	ARTICLE	IF	CITATIONS
1	Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. <i>Lancet, The</i> , 1997, 350, 1349-1353.	13.7	775
2	Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart Failure. <i>Circulation</i> , 2000, 101, 594-597.	1.6	493
3	High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid. <i>Circulation</i> , 2006, 114, 2508-2516.	1.6	492
4	Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 221-226.	1.6	449
5	Allopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics With Mild Hypertension. <i>Hypertension</i> , 2000, 35, 746-751.	2.7	402
6	Effect of vitamin D on blood pressure: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2009, 27, 1948-1954.	0.5	320
7	Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. <i>Lancet, The</i> , 2010, 375, 2161-2167.	13.7	301
8	Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1995, 76, 1259-1265.	1.6	296
9	What is the optimal serum potassium level in cardiovascular patients?. <i>Journal of the American College of Cardiology</i> , 2004, 43, 155-161.	2.8	288
10	Effect of Vitamin D Supplementation on Blood Pressure. <i>JAMA Internal Medicine</i> , 2015, 175, 745.	5.1	272
11	Pulse wave analysis and pulse wave velocity. <i>Journal of Hypertension</i> , 2003, 21, 463-472.	0.5	257
12	Review of aldosterone- and angiotensin II-induced target organ damage and prevention. <i>Cardiovascular Research</i> , 2004, 61, 663-670.	3.8	229
13	Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. <i>Cmaj</i> , 2007, 177, 867-874.	2.0	212
14	Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. <i>Clinical Science</i> , 2002, 103, 425-431.	4.3	205
15	Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. <i>Journal of Cardiac Failure</i> , 1996, 2, 47-54.	1.7	200
16	The Effects of Vitamin D Supplementation on Physical Function and Quality of Life in Older Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 195-201.	3.9	199
17	A Comparison of the Aldosterone-Blocking Agents Eplerenone and Spironolactone. <i>Clinical Cardiology</i> , 2008, 31, 153-158.	1.8	196
18	Allopurinol Benefits Left Ventricular Mass and Endothelial Dysfunction in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1382-1389.	6.1	191

#	ARTICLE	IF	CITATIONS
19	Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. <i>American Journal of Cardiology</i> , 1996, 77, 828-831.	1.6	181
20	Heart failure in frail elderly patients: diagnostic difficulties, comorbidities, polypharmacy and treatment dilemmas. <i>European Journal of Heart Failure</i> , 2002, 4, 91-98.	7.1	181
21	Myocardial Production of C-Type Natriuretic Peptide in Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 571-573.	1.6	171
22	Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. <i>Vascular Health and Risk Management</i> , 2009, 5, 265.	2.3	167
23	C-Type Natriuretic Peptide. <i>Peptides</i> , 1996, 17, 1243-1251.	2.4	162
24	High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. <i>European Heart Journal</i> , 2014, 35, 271-281.	2.2	160
25	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	2.2	148
26	Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure. <i>Circulation</i> , 2020, 142, 1713-1724.	1.6	144
27	Cardiovascular Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3112-3120.	2.8	143
28	Impact of Renin-Angiotensin System Blockade Therapy on Outcome in Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2011, 58, 570-576.	2.8	142
29	Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1800-1807.	2.8	140
30	A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. <i>European Heart Journal</i> , 2020, 41, 3421-3432.	2.2	138
31	Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. <i>Lancet</i> , 2002, 359, 1430-1432.	13.7	132
32	High-Dose Allopurinol Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 926-932.	2.8	132
33	Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 1996, 78, 284-287.	1.6	123
34	N-Terminal Pro-Brain Natriuretic Protein Levels in Takotsubo Cardiomyopathy. <i>American Journal of Cardiology</i> , 2011, 108, 1316-1321.	1.6	123
35	Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension. <i>JAMA Internal Medicine</i> , 2013, 173, 1672-9.	5.1	123
36	Left Ventricular Noncompaction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2157-2165.	2.8	118

#	ARTICLE	IF	CITATIONS
37	Adverse Cardiovascular Effects of Acute Salt Loading in Young Normotensive Individuals. Hypertension, 2008, 51, 1525-1530.	2.7	113
38	Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. American Heart Journal, 1994, 127, 1635-1636.	2.7	112
39	Mechanistic Insights Into the Therapeutic Use of High-Dose Allopurinol in Angina Pectoris. Journal of the American College of Cardiology, 2011, 58, 820-828.	2.8	110
40	Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clinical Science, 1992, 83, 519-527.	4.3	107
41	<i>DD</i> Angiotensin-Converting Enzyme Gene Polymorphism Is Associated With Endothelial Dysfunction in Normal Humans. Hypertension, 1999, 33, 1164-1168.	2.7	102
42	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care, 2020, 43, 1356-1359.	8.6	102
43	The clinical implications of aldosterone escape in congestive heart failure. European Journal of Heart Failure, 2004, 6, 539-545.	7.1	100
44	A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. European Heart Journal, 2019, 40, 3409-3417.	2.2	100
45	Effect of a Seated Exercise Program to Improve Physical Function and Health Status in Frail Patients ≥70 Years of Age With Heart Failure. American Journal of Cardiology, 2005, 95, 1120-1124.	1.6	99
46	Allopurinol Reduces Left Ventricular Mass in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy. Journal of the American College of Cardiology, 2013, 62, 2284-2293.	2.8	97
47	Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respiratory Medicine, the, 2014, 2, 293-300.	10.7	94
48	Peripheral blood pressure measurement is as good as applanation tonometry at predicting ascending aortic blood pressure. Journal of Hypertension, 2003, 21, 571-576.	0.5	90
49	Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clinical Science, 1992, 83, 529-533.	4.3	89
50	Assessment of Arterial Stiffness, A Translational Medicine Biomarker System for Evaluation of Vascular Risk. Cardiovascular Therapeutics, 2008, 26, 214-223.	2.5	89
51	Effect of Metformin on Mortality in Patients With Heart Failure and Type 2 Diabetes Mellitus. American Journal of Cardiology, 2010, 106, 1006-1010.	1.6	89
52	Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Kidney International, 2016, 90, 845-852.	5.2	88
53	Cardiovascular consequences of laparoscopic surgery. Lancet, The, 1998, 352, 568-570.	13.7	84
54	Insulin Resistance Is Highly Prevalent and Is Associated With Reduced Exercise Tolerance in Nondiabetic Patients With Heart Failure. Journal of the American College of Cardiology, 2009, 53, 747-753.	2.8	84

#	ARTICLE	IF	CITATIONS
55	Spironolactone use and renal toxicity: population based longitudinal analysis. <i>BMJ: British Medical Journal</i> , 2010, 340, c1768-c1768.	2.3	83
56	Impact of allopurinol use on urate concentration and cardiovascular outcome. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 600-607.	2.4	82
57	The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 1303-1310.	7.1	79
58	Targeting the renin-angiotensin-aldosterone system in heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 125-134.	13.7	78
59	Mean $\langle \text{HbA}_{1c} \rangle$ and mortality in diabetic individuals with heart failure: a population cohort study. <i>European Journal of Heart Failure</i> , 2016, 18, 94-102.	7.1	76
60	Aldosterone: Cardiovascular assault. <i>American Heart Journal</i> , 2002, 144, S2-S7.	2.7	75
61	Improving the Primary Prevention of Cardiovascular Events by Using Biomarkers to Identify Individuals With Silent Heart Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, 960-968.	2.8	75
62	Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. <i>BMJ: British Medical Journal</i> , 1997, 314, 936-936.	2.3	74
63	Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. <i>BMJ Open</i> , 2016, 6, e013774.	1.9	70
64	The Impact of Renin-Angiotensin-Aldosterone System Blockade on Heart Failure Outcomes and Mortality in Patients Identified to Have Aortic Regurgitation. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2084-2091.	2.8	68
65	Dietary sodium loading increases plasma brain natriuretic peptide levels in man. <i>Journal of Hypertension</i> , 1991, 9, 779-782.	0.5	66
66	Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. <i>Clinical Science</i> , 1992, 82, 127-131.	4.3	66
67	Brain natriuretic peptide. <i>Journal of Hypertension</i> , 1994, 12, 329-336.	0.5	65
68	Do ACE Inhibitors Improve the Response to Exercise Training in Functionally Impaired Older Adults? A Randomized Controlled Trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 736-743.	3.6	65
69	Effect of Vitamin D Supplementation on Markers of Vascular Function: A Systematic Review and Individual Participant Meta-Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	63
70	Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. <i>European Journal of Heart Failure</i> , 1999, 1, 401-406.	7.1	62
71	The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. <i>European Heart Journal</i> , 2007, 28, 1678-1682.	2.2	61
72	Effects of Vitamin D supplementation on markers of vascular function after myocardial infarction: A randomised controlled trial. <i>International Journal of Cardiology</i> , 2013, 167, 745-749.	1.7	60

#	ARTICLE	IF	CITATIONS
73	The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?. <i>Journal of Hypertension</i> , 2002, 20, 11-15.	0.5	59
74	Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2002, 39, 767-775.	2.8	59
75	Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. <i>Arthritis and Rheumatism</i> , 2012, 64, 327-338.	6.7	58
76	Efficacy and Cost of an Exercise Program for Functionally Impaired Older Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 209-216.	3.9	57
77	Vitamin D Therapy to Reduce Blood Pressure and Left Ventricular Hypertrophy in Resistant Hypertension. <i>Hypertension</i> , 2014, 63, 706-712.	2.7	57
78	Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. <i>British Heart Journal</i> , 2002, 87, 97-98.	2.1	55
79	Twenty-Year Predictors of Peripheral Arterial Disease Compared With Coronary Heart Disease in the Scottish Heart Health Extended Cohort (SHHEC). <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	54
80	Irbesartan Reduces QT Dispersion in Hypertensive Individuals. <i>Hypertension</i> , 1999, 33, 713-718.	2.7	52
81	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. <i>Cardiovascular Diabetology</i> , 2016, 15, 97.	6.8	49
82	Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2434-2445.	6.1	49
83	Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. <i>European Journal of Heart Failure</i> , 2012, 14, 162-167.	7.1	48
84	The role of pulmonary arterial stiffness in COPD. <i>Respiratory Medicine</i> , 2015, 109, 1381-1390.	2.9	46
85	Adverse Cardiac Effects of Salt With Fludrocortisone in Hypertension. <i>Hypertension</i> , 2001, 37, 856-861.	2.7	45
86	Enalapril Reduces QTc Dispersion in Mild Congestive Heart Failure Secondary to Coronary Artery Disease. <i>American Journal of Cardiology</i> , 1997, 79, 328-333.	1.6	43
87	Sarcopenia – A Potential Target for Angiotensin-Converting Enzyme Inhibition?. <i>Gerontology</i> , 2006, 52, 237-242.	2.8	43
88	Angiotensin II augments sympathetically mediated arteriolar constriction in man. <i>Clinical Science</i> , 1991, 81, 261-266.	4.3	42
89	Relation of QT interval dispersion to the number of different cardiac abnormalities in diabetes mellitus. <i>American Journal of Cardiology</i> , 2002, 90, 483-487.	1.6	42
90	The Functional Consequence of the Glu298Asp Polymorphism of the Endothelial Nitric Oxide Synthase Gene in Young Healthy Volunteers. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 280-288.	4.1	42

#	ARTICLE	IF	CITATIONS
91	Allopurinol Treatment Reduces Arterial Wave Reflection in Stroke Survivors. <i>Cardiovascular Therapeutics</i> , 2008, 26, 247-252.	2.5	42
92	C-Type Natriuretic Peptide. <i>Circulation</i> , 1996, 93, 1155-1159.	1.6	42
93	Both High and Low HbA1c Predict Incident Heart Failure in Type 2 Diabetes Mellitus. <i>Circulation: Heart Failure</i> , 2015, 8, 236-242.	3.9	41
94	Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 6.	1.6	39
95	Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. <i>BMJ Open</i> , 2017, 7, e018097.	1.9	38
96	Aldosterone blockade in cardiovascular disease. <i>Heart</i> , 2004, 90, 1229-1234.	2.9	37
97	Predictors of exercise capacity and everyday activity in older heart failure patients. <i>European Journal of Heart Failure</i> , 2006, 8, 203-207.	7.1	37
98	Lack of rapid aldosterone effects on forearm resistance vasculature in health. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 123-125.	1.7	36
99	Effects of Exogenous and Endogenous Natriuretic Peptides on Forearm Vascular Function in Chronic Heart Failure. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 911-917.	2.4	36
100	Exercise Training as a Therapy for Chronic Heart Failure: Can Older People Benefit?. <i>Journal of the American Geriatrics Society</i> , 2003, 51, 699-709.	2.6	35
101	Meta-Analysis of B-Type Natriuretic Peptide's Ability to Identify Stress Induced Myocardial Ischemia. <i>American Journal of Cardiology</i> , 2011, 107, 662-667.	1.6	35
102	Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 479-482.	2.4	34
103	Aldosterone-induced vasculopathy. <i>Molecular and Cellular Endocrinology</i> , 2004, 217, 239-241.	3.2	34
104	Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. <i>Journal of Hypertension</i> , 2007, 25, 2345-2351.	0.5	34
105	Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?. <i>Clinical Endocrinology</i> , 2011, 75, 725-729.	2.4	34
106	The Role of Urate and Xanthine Oxidase Inhibitors in Cardiovascular Disease. <i>Cardiovascular Drug Reviews</i> , 2008, 26, 59-64.	4.1	33
107	Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. <i>American Heart Journal</i> , 1993, 126, 879-886.	2.7	32
108	Nonadherence with angiotensin-converting enzyme inhibitor therapy. <i>Journal of the American College of Cardiology</i> , 1999, 34, 2072-2077.	2.8	32

#	ARTICLE	IF	CITATIONS
109	A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2009, 11, 980-989.	7.1	32
110	The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes. <i>Journal of the American College of Cardiology</i> , 2002, 39, 219-224.	2.8	31
111	Elevated levels of natriuretic peptides in patients with pulmonary thromboembolism. <i>Respiratory Medicine</i> , 2005, 99, 1286-1291.	2.9	31
112	Impact of Aldosterone on Vascular Pathophysiology. <i>Congestive Heart Failure</i> , 2002, 8, 18-22.	2.0	29
113	Tolerability of spironolactone in patients with chronic heart failure - a cautionary message. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 554-557.	2.4	28
114	Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities. <i>American Heart Journal</i> , 2009, 158, 133-140.	2.7	28
115	Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males. <i>Journal of Hypertension</i> , 1995, 13, 667-673.	0.5	27
116	B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. <i>Age and Ageing</i> , 2002, 31, 295-301.	1.6	27
117	Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. <i>Journal of Hypertension</i> , 2010, 28, 170-177.	0.5	27
118	Allopurinol: novel indications in cardiovascular disease. <i>Heart</i> , 2012, 98, 1543-1545.	2.9	27
119	Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 622-631.	2.4	26
120	B-type natriuretic peptide: a simple new test to identify coronary artery disease?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 765-769.	0.5	26
121	Therapeutic Development in Cardiac Syndrome X: A Need to Target the Underlying Pathophysiology. <i>Cardiovascular Therapeutics</i> , 2009, 27, 49-58.	2.5	26
122	Left Ventricular Hypertrophy in COPD Without Hypoxemia. <i>Chest</i> , 2013, 143, 91-97.	0.8	26
123	Association between GDF-15 levels and changes in vascular and physical function in older patients with hypertension. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 1055-1059.	2.9	26
124	Xanthine oxidase inhibition for the improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST) – Protocol for a randomised double blind placebo-controlled clinical trial. <i>European Stroke Journal</i> , 2018, 3, 281-290.	5.5	26
125	Pathophysiology of heart failure following myocardial infarction. <i>Heart</i> , 2005, 91, ii14-ii16.	2.9	25
126	The role of urate and xanthine oxidase in vascular oxidative stress: future directions. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 799.	2.0	25

#	ARTICLE	IF	CITATIONS
127	Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 229.	1.7	25
128	B-type natriuretic peptide is an independent predictor of endothelial function in man. <i>Clinical Science</i> , 2012, 123, 307-312.	4.3	24
129	Hypertensive left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2012, 30, 2039-2046.	0.5	24
130	B-Type Natriuretic Peptide Is Associated With Both Augmentation Index and Left Ventricular Mass in Diabetic Patients Without Heart Failure. <i>American Journal of Hypertension</i> , 2005, 18, 1586-1591.	2.0	23
131	Adherence to angiotensinâ€convertingâ€enzyme inhibitors and illness beliefs in older heart failure patients. <i>European Journal of Heart Failure</i> , 2009, 11, 715-720.	7.1	23
132	Do Losartan and Atenolol have Differential Effects on BNP and Central Haemodynamic Parameters?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005, 6, 151-153.	1.7	22
133	The Cardiovascular Risk Factor, Left Ventricular Hypertrophy, Is Highly Prevalent in Stable, Treated Angina Pectoris. <i>American Journal of Hypertension</i> , 2007, 20, 1029-1035.	2.0	22
134	High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. <i>Heart</i> , 2014, 100, 867-872.	2.9	22
135	Effects of an exercise intervention for older heart failure patients on caregiver burden and emotional distress. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006, 13, 381-387.	2.8	22
136	Mechanisms of the antinatriuretic action of physiological doses of angiotensin II in man. <i>Clinical Science</i> , 1989, 76, 653-658.	4.3	21
137	B-Type Natriuretic Peptide as an Alternative Way of Assessing Total Cardiovascular Risk in Patients With Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2005, 96, 933-934.	1.6	21
138	Effect of spironolactone on C-reactive protein levels in patients with heart disease. <i>International Journal of Cardiology</i> , 2007, 117, 282-284.	1.7	21
139	The association between serum urate levels and arterial stiffness/endothelial function in stroke survivors. <i>Atherosclerosis</i> , 2008, 200, 374-379.	0.8	21
140	Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study. <i>Clinical and Experimental Hypertension</i> , 2015, 37, 308-316.	1.3	21
141	The prognostic value of high sensitivity troponin T 7 weeks after an acute coronary syndrome. <i>Heart</i> , 2012, 98, 1160-1165.	2.9	20
142	Interactions between atrial natriuretic factor and the autonomic nervous system. <i>Clinical Autonomic Research</i> , 1991, 1, 329-336.	2.5	19
143	Are Natriuretic Peptides Clinically Useful as Markers of Heart Failure?. <i>Annals of Clinical Biochemistry</i> , 2001, 38, 575-583.	1.6	19
144	Polymorphisms of the angiotensin converting enzyme gene in early-onset and late-onset pre-eclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010, 23, 874-879.	1.5	19

#	ARTICLE	IF	CITATIONS
145	Common Carotid Intima Media Thickness and Ankle-Brachial Pressure Index Correlate with Local but Not Global Atheroma Burden: A Cross Sectional Study Using Whole Body Magnetic Resonance Angiography. PLoS ONE, 2014, 9, e99190.	2.5	19
146	Development and Validation of a Path Length Calculation for Carotid-Femoral Pulse Wave Velocity Measurement. Hypertension, 2018, 71, 937-945.	2.7	19
147	Lisinopril improves arterial function in hyperlipidaemia. Clinical Science, 1999, 96, 441-448.	4.3	18
148	Beyond blood pressure: pulse wave analysis - a better way of assessing cardiovascular risk?. Future Cardiology, 2005, 1, 69-78.	1.2	18
149	Comparative Effects of Atrial Natriuretic Peptide and Brain Natriuretic Peptide on the Aldosterone and Pressor Responses to Angiotensin II in Man. Clinical Science, 1995, 88, 81-86.	4.3	17
150	Effect of phenylephrine with and without atropine on QT dispersion in healthy normotensive men. American Journal of Cardiology, 2000, 85, 69-74.	1.6	17
151	Hyperuricemia and Adverse Outcomes in Cardiovascular Disease. American Journal of Cardiovascular Drugs, 2003, 3, 309-314.	2.2	17
152	Effects of an exercise intervention for older heart failure patients on caregiver burden and emotional distress. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 381-387.	2.8	17
153	Using the demand-control model of job strain to predict caregiver burden and caregiver satisfaction in the informal caregivers of heart failure patients. British Journal of Health Psychology, 2008, 13, 401-417.	3.5	17
154	Serial changes in adiponectin and BNP in ACS patients: paradoxical associations with each other and with prognosis. Clinical Science, 2009, 117, 41-48.	4.3	17
155	Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension. Journal of Hypertension, 2019, 37, 2481-2489.	0.5	17
156	Atrial natriuretic factor improves renal function and lowers systolic blood pressure in renal allograft recipients treated with cyclosporinA. Journal of Hypertension, 1992, 10, 483-488.	0.5	16
157	Nonadherence with ACE Inhibitors Is Common and Can Be Detected in Clinical Practice by Routine Serum ACE Activity. Congestive Heart Failure, 2001, 7, 43-50.	2.0	16
158	Effect of Spironolactone on Physical Performance in Older People with Self-reported Physical Disability. American Journal of Medicine, 2013, 126, 590-597.	1.5	16
159	Neuroendocrine changes post myocardial infarction: Effects of xamoterol. American Heart Journal, 1990, 120, 56-62.	2.7	15
160	B-Type Natriuretic Peptide Is Associated with Mortality in Older Functionally Impaired Patients. Journal of the American Geriatrics Society, 2005, 53, 1991-1995.	2.6	15
161	Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opinion on Pharmacotherapy, 2007, 8, 3053-3059.	1.8	15
162	Correlation of angiotensin converting enzyme activity and the genotypes of the I/D polymorphism in the ACE gene with preterm birth and birth weight. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 141, 27-30.	1.1	15

#	ARTICLE	IF	CITATIONS
163	Uric acid in chronic heart failure—current pathophysiological concepts*. <i>European Journal of Heart Failure</i> , 2008, 10, 1269-1270.	7.1	15
164	Optimization of the contrast dose and injection rates in whole-body MR angiography at 3.0T. <i>Journal of Magnetic Resonance Imaging</i> , 2009, 30, 1059-1067.	3.4	15
165	A New Approach to Residual Risk in Treated Hypertension—3P Screening. <i>Hypertension</i> , 2013, 62, 236-239.	2.7	15
166	A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 329-334.	2.4	14
167	Exercise Capacity and Brain Natriuretic Peptide in Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 40, 519-527.	1.9	14
168	Atrial Natriuretic Peptide Regulates Regional Vascular Volume and Venous Tone in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1833-1838.	2.4	14
169	The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) Trial. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2405.	2.8	14
170	Insulin Sensitization Therapy and the Heart. <i>Heart Failure Clinics</i> , 2012, 8, 539-550.	2.1	14
171	High BNP levels in rheumatoid arthritis are related to inflammation but not to left ventricular abnormalities: A prospective case-control study. <i>International Journal of Cardiology</i> , 2014, 172, e116-e118.	1.7	14
172	The Practical Assessment of Compliance with ACE-Inhibitor Therapy-A Novel Approach. <i>Journal of Cardiovascular Pharmacology</i> , 1997, 29, 119-124.	1.9	14
173	Lisinopril improves endothelial function in chronic cigarette smokers. <i>Clinical Science</i> , 2001, 101, 53.	4.3	13
174	Age is not a significant risk factor for failed trial of beta-blocker therapy in older patients with chronic heart failure. <i>Age and Ageing</i> , 2004, 33, 467-472.	1.6	13
175	Aldosterone in heart failure: Pathophysiology and treatment. <i>Current Heart Failure Reports</i> , 2004, 1, 171-175.	3.3	13
176	C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure. <i>Clinical Science</i> , 2010, 118, 71-77.	4.3	13
177	Pulmonary arterial stiffening in COPD and its implications for right ventricular remodelling. <i>European Radiology</i> , 2018, 28, 3464-3472.	4.5	13
178	Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 858-871.	7.3	13
179	Nitric oxide: an important role in the maintenance of systemic and pulmonary vascular tone in man. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 263-266.	2.4	12
180	Review: Aldosterone-induced vasculopathy: a new reversible cause of cardiac death. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, 211-214.	1.7	12

#	ARTICLE	IF	CITATIONS
181	Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, 20-30.	1.7	12
182	Effect of vitamin D supplementation on orthostatic hypotension. <i>Journal of Hypertension</i> , 2014, 32, 1693-1699.	0.5	12
183	The effect of perindopril on postural instability in older people with a history of falls—a randomised controlled trial. <i>Age and Ageing</i> , 2018, 47, 75-81.	1.6	12
184	The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure. , 1992, 53, 187-197.		11
185	Time course for recovery of atrial mechanical and endocrine function post DC cardioversion for persistent atrial fibrillation. <i>International Journal of Cardiology</i> , 2005, 102, 487-491.	1.7	11
186	A critical re-appraisal of different ways of selecting ambulatory patients with suspected heart failure for echocardiography. <i>European Journal of Heart Failure</i> , 2007, 9, 55-61.	7.1	11
187	3T MRI investigation of cardiac left ventricular structure and function in a UK population: The tayside screening for the prevention of cardiac events (TASCFORCE) study. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1186-1196.	3.4	11
188	A Randomized Controlled Trial of Allopurinol in Patients With Peripheral Arterial Disease. <i>Canadian Journal of Cardiology</i> , 2016, 32, 190-196.	1.7	11
189	Effectiveness of captopril in reversing renal vasoconstriction after Q-wave acute myocardial infarction. <i>American Journal of Cardiology</i> , 1993, 71, 281-286.	1.6	10
190	Long-term Follow-up of Very Old Heart Failure Patients Enrolled in a Trial of Exercise Training. <i>The American Journal of Geriatric Cardiology</i> , 2007, 16, 243-248.	0.6	10
191	Development and Validation of a Clinical Score to Identify Echocardiographic Left Ventricular Hypertrophy in Patients With Cardiovascular Disease. <i>American Journal of Hypertension</i> , 2008, 21, 1011-1017.	2.0	10
192	An Increased B-Type Natriuretic Peptide in the Absence of a Cardiac Abnormality Identifies Those Whose Left Ventricular Mass Will Increase Over Time. <i>JACC: Heart Failure</i> , 2015, 3, 87-93.	4.1	10
193	Prevalence of unrecognized myocardial infarction in a low-intermediate risk asymptomatic cohort and its relation to systemic atherosclerosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 18, jew155.	1.2	10
194	Prazosin blunts the antinatriuretic effect of circulating angiotensin II in man. <i>Journal of Hypertension</i> , 1992, 10, 1387-1395.	0.5	9
195	Aldosterone blockade in heart failure.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, S23.	1.7	9
196	Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus. <i>Diabetologia</i> , 2007, 50, 2061-2066.	6.3	9
197	Right ventricular pacing impairs endothelial function in man. <i>Europace</i> , 2011, 13, 853-858.	1.7	9
198	Renal, hemodynamic and neurohormonal effects of atrial natriuretic factor in cardiac allograft recipients treated with cyclosporin A. <i>American Journal of Cardiology</i> , 1993, 72, 1083-1084.	1.6	8

#	ARTICLE	IF	CITATIONS
199	Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1994, 73, 1191-1196.	1.6	8
200	Autonomic Effects of Spironolactone and MR Blockers in Heart Failure. <i>Heart Failure Reviews</i> , 2005, 10, 63-69.	3.9	8
201	Aortic valvular heart disease: is there a place for angiotensin-converting-enzyme inhibitors?. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 107-114.	1.5	8
202	The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs). <i>Clinical Genitourinary Cancer</i> , 2016, 14, 398-405.	1.9	8
203	Effects of contrast administration on cardiac MRI volumetric, flow and pulse wave velocity quantification using manual and software-based analysis. <i>British Journal of Radiology</i> , 2018, 91, 20170717.	2.2	8
204	The <sc>APEX</sc> trial: Effects of allopurinol on exercise capacity, coronary and peripheral endothelial function, and natriuretic peptides in patients with cardiac syndrome X. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12311.	2.5	8
205	A Randomized, Controlled Trial of the Effect of Allopurinol on Left Ventricular Mass Index in Hemodialysis Patients. <i>Kidney International Reports</i> , 2021, 6, 146-155.	0.8	8
206	Recruitment strategies for sarcopenia trials: lessons from the LACE randomized controlled trial. <i>JCSM Rapid Communications</i> , 2021, 4, 93-102.	1.6	8
207	Screening for left ventricular systolic dysfunction using GP-reported ECGs. <i>British Journal of General Practice</i> , 2007, 57, 191-5.	1.4	8
208	Prazosin attenuates the natriuretic response to atrial natriuretic factor in man. <i>Kidney International</i> , 1992, 42, 433-441.	5.2	7
209	Effect of pericardiocentesis on plasma levels of brain natriuretic peptide in cardiac tamponade. <i>American Journal of Cardiology</i> , 1992, 70, 1628-1629.	1.6	7
210	Ovarian hormones in man: their effects on resting vascular tone, angiotensin converting enzyme activity and angiotensin II-induced vasoconstriction. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 73-76.	2.4	7
211	Screening for treatable left ventricular abnormalities in diabetic patients. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 107-112.	3.1	7
212	How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?. <i>Journal of Hypertension</i> , 2004, 22, 1403-1408.	0.5	7
213	Left ventricular hypertrophy is present in one-half of newly-diagnosed peripheral arterial disease patients. <i>Journal of Hypertension</i> , 2007, 25, 463-469.	0.5	7
214	Impact of Left Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease. <i>Lung</i> , 2015, 193, 487-495.	3.3	7
215	Prevalence and Distribution of Atherosclerosis in a Low- to Intermediate-Risk Population: Assessment with Whole-Body MR Angiography. <i>Radiology</i> , 2018, 287, 795-804.	7.3	7
216	Disconnection of pulmonary and systemic arterial stiffness in COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 1755-1765.	2.3	7

#	ARTICLE	IF	CITATIONS
217	Systemic arteriosclerosis is associated with left ventricular remodeling but not atherosclerosis: a TASCFORCE study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2018, 20, 7.	3.3	7
218	Cyclosporin-induced renal vasoconstriction is augmented by frusemide and by angiotensin II in humans. <i>Journal of Hypertension</i> , 1995, 13, 987-991.	0.5	6
219	Should we add screening for and treating left ventricular hypertrophy to the management of all patients needing secondary prevention of cardiovascular disease?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 449-452.	0.5	6
220	Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study. <i>BMC Cardiovascular Disorders</i> , 2007, 7, 14.	1.7	6
221	Family history of premature coronary heart disease and risk prediction. <i>Heart</i> , 2011, 97, 684-684.	2.9	6
222	Myocardial ischaemia is associated with an elevated brain natriuretic peptide level even in the presence of left ventricular systolic dysfunction. <i>European Journal of Heart Failure</i> , 2014, 16, 56-67.	7.1	6
223	Assessment of proximal pulmonary arterial stiffness using magnetic resonance imaging: effects of technique, age and exercise. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000149.	3.0	6
224	Whole body cardiovascular magnetic resonance imaging to stratify symptomatic and asymptomatic atherosclerotic burden in patients with isolated cardiovascular disease. <i>BMC Medical Imaging</i> , 2016, 16, 18.	2.7	6
225	Myocardial changes in incident haemodialysis patients over 6-months: an observational cardiac magnetic resonance imaging study. <i>Scientific Reports</i> , 2017, 7, 13976.	3.3	6
226	Evidence for myocardial synthesis of aldosterone producing myocardial fibrosis in man. <i>Clinical Science</i> , 2002, 102, 387.	4.3	6
227	Enalapril blunts the antinatriuretic effect of circulating noradrenaline in man. <i>Journal of Hypertension</i> , 1993, 11, 565-572.	0.5	5
228	Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone. <i>Clinical Science</i> , 1998, 95, 513-517.	4.3	5
229	More evidence for bedside BNP in heart failure assessment. <i>International Journal of Cardiology</i> , 2002, 86, 149-152.	1.7	5
230	Review: The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 150-155.	1.7	5
231	Diagnosis and management of heart failure: implications of the recent European Society of Cardiology Guidelines for the older patient. <i>Age and Ageing</i> , 2003, 32, 563-565.	1.6	5
232	The influence of mode of delivery and ACE genotype on serum angiotensin converting enzyme (ACE) activity in the mother and infant at term. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 134, 179-183.	1.1	5
233	Biomarkers and Surrogate Endpoints in Cardiovascular Therapeutics Research: Under Scrutiny Following Results of the ENHANCE Study. <i>Cardiovascular Therapeutics</i> , 2008, 26, 85-88.	2.5	5
234	Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. <i>Heart Rhythm</i> , 2012, 9, 505-510.	0.7	5

#	ARTICLE	IF	CITATIONS
235	Research cardiac magnetic resonance imaging in end stage renal disease - incidence, significance and implications of unexpected incidental findings. <i>European Radiology</i> , 2017, 27, 315-324.	4.5	5
236	An Open-Label Dose-Finding Study of Allopurinol to Target Defined Reduction in Urate Levels in Hemodialysis Patients. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1409-1414.	2.0	5
237	Metformin regresses left ventricular hypertrophy in normotensive patients with coronary artery disease without type 2 diabetes mellitus - the met-remodel trial. , 2018, , .		5
238	Effect of allopurinol on phosphocreatine recovery and muscle function in older people with impaired physical function: a randomised controlled trial. <i>Age and Ageing</i> , 2020, 49, 1003-1010.	1.6	5
239	The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 150.	1.7	5
240	The differential effects of circulating norepinephrine and neuronally released norepinephrine on sodium excretion in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 54, 514-522.	4.7	4
241	Heart failure: a diagnostic and therapeutic dilemma in elderly patients. <i>Age and Ageing</i> , 1998, 27, 539-543.	1.6	4
242	Lisinopril improves arterial function in hyperlipidaemia. <i>Clinical Science</i> , 1999, 96, 441.	4.3	4
243	Pathophysiology of aldosterone and its antagonists. <i>Fundamental and Clinical Pharmacology</i> , 2000, 14, 549-552.	1.9	4
244	Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients. <i>Heart</i> , 2006, 92, 1728-1731.	2.9	4
245	Natriuretic Peptides. , 2007, , 349-362.		4
246	The effect of nitric oxide inhibition on the renin response to frusemide, in man. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 355-360.	2.4	3
247	The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 29-36.	1.5	3
248	Global Array-Based Transcriptomics from Minimal Input RNA Utilising an Optimal RNA Isolation Process Combined with SPIA cDNA Probes. <i>PLoS ONE</i> , 2011, 6, e17625.	2.5	3
249	Novel Blockers of the Renin-Angiotensin-Aldosterone System in Chronic Heart Failure. <i>Current Heart Failure Reports</i> , 2014, 11, 31-39.	3.3	3
250	High B-Type Natriuretic Peptide Hypertensives at Target Blood Pressure. <i>Hypertension</i> , 2015, 66, 927-932.	2.7	3
251	Spirolactone for People Age 70 Years and Older With Osteoarthritic Knee Pain: A Proof-of-Concept Trial. <i>Arthritis Care and Research</i> , 2016, 68, 716-721.	3.4	3
252	Follow-up of atheroma burden with sequential whole body contrast enhanced MR angiography: a feasibility study. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 825-832.	1.5	3

#	ARTICLE	IF	CITATIONS
253	Whole-body cardiovascular MRI for the comparison of atherosclerotic burden and cardiac remodelling in healthy South Asian and European adults. <i>British Journal of Radiology</i> , 2016, 89, 20160342.	2.2	3
254	Pentaerythrityl tetranitrate (PETN): a better nitrate?. <i>European Heart Journal</i> , 2019, 40, e23-e25.	2.2	3
255	<p>Allopurinol in Patients with Pulmonary Hypertension Associated with Chronic Lung Disease</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2015-2024.	2.3	3
256	Prevalence of Symptomatic Diastolic Heart Failure in Patients Hospitalized With Cerebral or Peripheral Vascular Disease. <i>Congestive Heart Failure</i> , 2005, 11, 256-261.	2.0	2
257	Polymorphisms of the angiotensin converting enzyme gene in relation to intrauterine growth restriction. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 1197-1201.	2.8	2
258	MRI of the left atrium at 3T: evaluation of measurement reproducibility in healthy volunteers and patients with cardiovascular disease. <i>Acta Radiologica</i> , 2016, 57, 1468-1475.	1.1	2
259	Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone. <i>Clinical Science</i> , 1998, 95, 513.	4.3	1
260	Annual Scientific Meeting of ASCEPT, 1999 Careful Screening To Target Interventions To Prevent Sudden Cardiac Death. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2001, 28, 219-222.	1.9	1
261	Response to Letter Regarding Article, "The Effects of Vitamin D Supplementation on Physical Function and Quality of Life in Older Heart Failure Patients: A Randomized Controlled Trial" <i>Circulation: Heart Failure</i> , 2010, 3, .	3.9	1
262	Chronic Cardiac Failure. , 2010, , 272-285.		1
263	Letter to the editor: Comparing pace and speed in the pulmonary circulation?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H949-H949.	3.2	1
264	Acceptability and feasibility of magnetic femoral nerve stimulation in older, functionally impaired patients. <i>BMC Research Notes</i> , 2018, 11, 394.	1.4	1
265	Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)" <i>Circulation</i> , 2021, 144, e38-e39.	1.6	1
266	Clinical case studies in heart failure management. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 239-247.	2.4	0
267	Grossly elevated serum angiotensin-converting enzyme activities are still suppressible with ACE inhibitor therapy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002, 3, 138-138.	1.7	0
268	Should hospitals have a designated consultant with a specific interest in heart failure?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 877-879.	0.5	0
269	"Serum potassium level and risk of postoperative atrial fibrillation in patients undergoing cardiac surgery" Reply. <i>Journal of the American College of Cardiology</i> , 2004, 44, 939.	2.8	0
270	Letter by Struthers et al Regarding Article, "Cross-Sectional Relations of Multiple Biomarkers From Distinct Biological Pathways to Brachial Artery Endothelial Function" <i>Circulation</i> , 2006, 114, e383; author reply e384.	1.6	0

#	ARTICLE	IF	CITATIONS
271	Response to Letter Regarding Article, "High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid". <i>Circulation</i> , 2007, 115, .	1.6	0
272	Review: Aldosterone antagonism in type 2 diabetes mellitus " a new therapeutic approach to diabetic macrovascular disease?. <i>British Journal of Diabetes and Vascular Disease</i> , 2008, 8, 16-19.	0.6	0
273	Reducing Cardiovascular Risk in Patients following MI with Eplerenone. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S5231.	0.4	0
274	Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery. <i>Heart</i> , 2010, 96, 1254-1254.	2.9	0
275	High-dose allopurinol in patients with stable angina pectoris " Authors' reply. <i>Lancet</i> , The, 2010, 376, 1299-1300.	13.7	0
276	TO034NON-CONTRAST CARDIAC MAGNETIC RESONANCE T1 MAPPING AS A MARKER OF MYOCARDIAL FIBROSIS IN END STAGE RENAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i75-i75.	0.7	0
277	015...Prevalence, pattern and significance of late gadolinium enhancement in a healthy asymptomatic cohort. <i>Heart</i> , 2016, 102, A5.3-A5.	2.9	0
278	014...Patterns of early atherosclerosis formation and cardiac remodelling in healthy adults of south asian and european descent. <i>Heart</i> , 2016, 102, A5.2-A5.	2.9	0
279	15...No association between systemic arteriosclerosis and atherosclerosis on cardiac MRI and whole body angiography: the tascforce study. , 2017, , .		0
280	FP802EFFECT OF ALLOPURINOL ON LEFT VENTRICULAR MASS INDEX IN HAEMODIALYSIS PATIENTS - A RANDOMISED CONTROLLED TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i633-i633.	0.7	0
281	Reply. <i>Journal of Hypertension</i> , 2020, 38, 177-178.	0.5	0
282	Association between mitochondrial function measured by 31P magnetic resonance spectroscopy and physical performance in older people with functional impairment. <i>JCSM Clinical Reports</i> , 2021, 6, 71-79.	1.3	0